Form 4: Integra LifeSciences Grants EVP 70,305 RSUs

Integra LifeSciences Holdings Corp. granted its EVP, Chief Legal Officer & Secretary, Michael Damon Hutchinson, 70,305 restricted stock units with a future vesting schedule.

Summary

• Michael Damon Hutchinson, Executive Vice President, Chief Legal Officer & Secretary of Integra LifeSciences Holdings Corp. (IART), was granted 70,305 Restricted Stock Units (RSUs).
• The grant date for these RSUs is March 11, 2026.
• The RSUs will vest over three years: 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the grant date.
• Following this transaction, Hutchinson beneficially owns 159,911 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at long-term retention and alignment of interests, without indicating any immediate operational or financial changes.

Positives

• The grant of 70,305 Restricted Stock Units to a key executive aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention and sustained performance over a three-year period.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends through March 2029, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units with multi-year vesting, are a standard practice across the life sciences and medical technology industries to incentivize and retain key executives. This aligns Integra LifeSciences with common corporate governance and compensation strategies seen in competitors.

Comparison to Industry Standards

• The grant of RSUs to a Chief Legal Officer is a common practice in large publicly traded companies, comparable to compensation structures at peers like Medtronic or Stryker, which also utilize long-term equity incentives to retain senior management.
• The three-year vesting schedule is typical for executive equity awards, aiming to align executive performance with shareholder returns over a sustained period, similar to programs observed at companies such as Johnson & Johnson or Abbott Laboratories.

Stakeholder Impact

• Shareholders: Potential positive impact through increased executive alignment with long-term company performance.
• Employees: No direct impact on general employees, but may signal stability in executive leadership.

Next Steps

• The granted RSUs will vest in three tranches on March 11, 2027, March 11, 2028, and March 11, 2029.

Key Dates

Recommendation

This Form 4 filing details a routine executive equity grant and does not provide new information that would significantly alter the fundamental investment thesis for Integra LifeSciences. It reinforces executive retention but does not indicate any immediate operational or financial catalysts for a 'buy' or 'sell' recommendation.

Keywords

Integra LifeSciences, IART, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Michael Damon Hutchinson, Equity Grant